参考文献/References:
[1] Fuster V, Ryden LE, Cannom DS, et al.2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J]. Circulation, 2011,123:e269-e367.
[2] January CT, Wann LS, Alpert JS,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society[J]. Circulation,2014,130:2071-2104.
[3] Falk RH. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation[J]. Ann Intern Med,1989,111:107-111.
[4] Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone[J]. Cardiovasc Res, 1997,35:13-29.
[5] Rizza C, Valderrabano M, Singh BN.Recurrent torsades de pointes after sotalol therapy for symptomatic paroxysmal atrial fibrillation in a patient with end-stage renal disease[J]. J Cardiovasc Pharmacol Ther,1999,4:129-134.
[6] Tse HF, Lam YM, Lau CP,et al.Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation[J]. Clin Exp Pharmacol Physiol,2001,28:446-450.
[7] Baroletti S, Catella J, Ehle M,et al. Dronedarone: a review of characteristics and clinical data[J]. Crit Pathw Cardiol,2010,9:94-101.
[8] Davy JM, Herold M, Hoglund C,et al.Dronedarone for the control of ventricular rate in permanent atrial fibrillation:the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation(ERATO)study[J]. Am Heart J,2008,156:527,e521-529.
[9] Hohnloser SH, Crijns HJ, van EickelsM, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation[J]. N Engl J Med,2009,360:668-678.
[10] le Heuzey JY,de Ferrari GM, Radzik D, et al.A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The dionysos study[J]. J Cardiovasc Electrophysiol,2010,21:597-605.
[11] Salam AM. Dronedarone in atrial fibrillation:the aftermath of the pallas trial[J]. Exp Rev Cardiovasc Ther, 2012,10:1345-1349.
[12] Roy D, Rowe BH, Stiell IG,et al.A randomized, controlled trial of rsd1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation[J]. J Am Coll Cardiol,2004,44:2355-2361.
[13] Pratt CM, Roy D, Torp-Pedersen C, et al. Atrial Arrhythmia Conversion Trial I. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation[J]. Am J Cardiol,2010,106:1277-1283.
[14] Roy D, Pratt CM, Torp-Pedersen C,et al.Atrial Arrhythmia Conversion Trial I. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial[J]. Circulation, 2008,117:1518-1525.
[15] Blaauw Y, Gogelein H, Tieleman RG,et al.“Early” class Ⅲ drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat[J]. Circulation,2004,110:1717-1724.
[16] Crijns HJ,van Gelder IC, Walfridsson H, et al.Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009[J]. Heart Rhythm,2006,3:1321-1331.
[17] Hashimoto N, Yamashita T, Tsuruzoe N. Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation[J]. Pharmacol Res,2006,54:136-141.
[18] Burashnikov A, di Diego JM, Zygmunt AC, et al. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation[J]. Ann N Y Acad Sci,2008,1123:105-112.
[19] Burashnikov A, Antzelevitch C. Novel pharmacological targets for the rhythm control management of atrial fibrillation[J]. Pharmacol Ther,2011,132:300-313.
[20] Scirica BM, Morrow DA, Hod H,et al.Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36(MERLIN-TIMI 36)randomized controlled trial[J]. Circulation,2007,116:1647-1652.
[21] Fan X, Chen Y, Xing J,et al. Blocking effects of acehytisine on pacemaker currents(I(f))in sinoatrial node cells and human HCN4 channels expressed in xenopus laevis oocytes[J]. J Ethnopharmacol,2012,139(1):42-51.
[22] Roubille F, Tardif JC.New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels[J]. Circulation,2013,127:1986-1996.
[23] Fox K, Ford I, Steg PG,et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction(beautiful): a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2008,372:807-816.
[24] Swedberg K, Komajda M, Bohm M,et al.Ivabradine and outcomes in chronic heart failure(shift): a randomised placebo-controlled study[J]. Lancet,2010,376:875-885.
[25] Xue X,Yan GX. The funny current(if): is it a novel antiarrhythmic target to treat atrial fibrillation?[J]. J Cardiovasc Electrophysiol,2012,23:207-208.
[26] Martin RI, Pogoryelova O, Koref MS,et al.Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials[J]. Heart,2014,100:1506-1510.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(5):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[6]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[7]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[8]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(5):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[9]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[10]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]